Trade | Association for Accessible Medicines
Welcome Message - Blog from AAM President and CEO Dan Leonard: Generics: The Bridge to A Vaccine.

Trade

AAM Statement on USTR Lighthizer’s House Testimony on USMCA

WASHINGTON, DC (June 18, 2020) — The Association for Accessible Medicines (AAM) welcomed U.S. Trade Representative Ambassador Robert Lighthizer’s commitment during his testimony yesterday before the House Ways and Means Committee that the free trade agreement currently being negotiated, including with the United Kingdom, will not contain a provision requiring 10-years of biologic exclusivity.

AAM Statement on Signing USMCA into Law

WASHINGTON DC (January 29, 2020) – “The Association for Accessible Medicines applauds President Trump’s signing of the U.S.-Mexico-Canada Agreement, the new gold standard for free trade agreements. Not only will patients have greater access to affordable medicines as a result of the USMCA, but America’s patients can be assured that this agreement promotes competition, access and innovation, the three building blocks of America’s globally leading pharmaceutical industry.

AAM Statement on Senate Passage of USMCA Agreement

WASHINGTON DC (January 16, 2020) –  “The Association for Accessible Medicines strongly endorses the Senate’s bipartisan passage of the U.S.-Mexico-Canada Agreement. For the first time in a trade agreement, a balance between support for innovation and access to affordable medicines has been reached. This balance will not only allow the growth of U.S. brand, generic and biosimilar pharmaceutical companies, but will also support increased access to competitively priced medicines in the United States.

USMCA Trade Agreement: A Victory for America’s Patients — #FixedUSMCA

AAM is pleased that Congress and the Administration have made changes to USMCA that support open markets, greater competition and improved cost savings for patients and the three health care systems. The revised USMCA trade agreement creates greater opportunities for patients in Mexico, Canada and the United States to access less expensive medicines and promotes a competitive pharmaceutical market across the three countries.

Read the AAM press release: https://accessiblemeds.org/resources/press-releases/usmca-trade-agreement-victory-americas-patients

USMCA Trade Agreement: A Victory for America’s Patients

WASHINGTON DC (December 10, 2019) – Today’s agreement reached by the Congressional Trade Working Group and the Trump administration represents a victory for patients.

The revised text creates greater opportunities for patients in Mexico, Canada and the United States to access less expensive medicines and promotes a competitive pharmaceutical market across the three countries. The improved pharmaceutical provisions create the balance between access to medicines and support for innovation that was included in bipartisan 2015 Trade Promotion Authority legislation.

AAM's Karin Hessler Provides an Inside Look at the GRx+Biosims 2019 Legal Track

Karin Hessler, Assistant General Counsel at the Association for Accessible Medicines, urges attendees to add their voice to the discussion at the one essential generic and biosimilar conference of the year: GRx+Biosims 2019, November 4—6 in Bethesda, MD.

The conference legal track:

The House Has Spoken – It’s Time to Fix USMCA’s Pharmaceutical Provisions

In a letter given to U.S. Trade Representative Robert Lighthizer today, 102 members of the House of Representatives expressed strong concern that the pharmaceutical provisions included in the U.S.-Mexico-Canada Agreement (USMCA) – NAFTA 2.0 – could increase prices for medicines in the United States, while limiting the ability of Congress to lessen pharmaceutical monopoly rights.

Subscribe to Trade

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.